Cargando…

Absolute Quantification of Phosphor‐Containing Metabolites in the Liver Using (31)P MRSI and Hepatic Lipid Volume Correction at 7T Suggests No Dependence on Body Mass Index or Age

BACKGROUND: Hepatic disorders are often associated with changes in the concentration of phosphorus‐31 ((31)P) metabolites. Absolute quantification offers a way to assess those metabolites directly but introduces obstacles, especially at higher field strengths (B(0) ≥ 7T). PURPOSE: To introduce a fea...

Descripción completa

Detalles Bibliográficos
Autores principales: Pfleger, Lorenz, Gajdošík, Martin, Wolf, Peter, Smajis, Sabina, Fellinger, Paul, Kuehne, Andre, Krumpolec, Patrik, Trattnig, Siegfried, Winhofer, Yvonne, Krebs, Michael, Krššák, Martin, Chmelík, Marek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6586048/
https://www.ncbi.nlm.nih.gov/pubmed/30291654
http://dx.doi.org/10.1002/jmri.26225
_version_ 1783428827875115008
author Pfleger, Lorenz
Gajdošík, Martin
Wolf, Peter
Smajis, Sabina
Fellinger, Paul
Kuehne, Andre
Krumpolec, Patrik
Trattnig, Siegfried
Winhofer, Yvonne
Krebs, Michael
Krššák, Martin
Chmelík, Marek
author_facet Pfleger, Lorenz
Gajdošík, Martin
Wolf, Peter
Smajis, Sabina
Fellinger, Paul
Kuehne, Andre
Krumpolec, Patrik
Trattnig, Siegfried
Winhofer, Yvonne
Krebs, Michael
Krššák, Martin
Chmelík, Marek
author_sort Pfleger, Lorenz
collection PubMed
description BACKGROUND: Hepatic disorders are often associated with changes in the concentration of phosphorus‐31 ((31)P) metabolites. Absolute quantification offers a way to assess those metabolites directly but introduces obstacles, especially at higher field strengths (B(0) ≥ 7T). PURPOSE: To introduce a feasible method for in vivo absolute quantification of hepatic (31)P metabolites and assess its clinical value by probing differences related to volunteers' age and body mass index (BMI). STUDY TYPE: Prospective cohort. SUBJECTS/PHANTOMS: Four healthy volunteers included in the reproducibility study and 19 healthy subjects arranged into three subgroups according to BMI and age. Phantoms containing (31)P solution for correction and validation. FIELD STRENGTH/SEQUENCE: Phase‐encoded 3D pulse‐acquire chemical shift imaging for (31)P and single‐volume (1)H spectroscopy to assess the hepatocellular lipid content at 7T. ASSESSMENT: A phantom replacement method was used. Spectra located in the liver with sufficient signal‐to‐noise ratio and no contamination from muscle tissue, were used to calculate following metabolite concentrations: adenosine triphosphates (γ‐ and α‐ATP); glycerophosphocholine (GPC); glycerophosphoethanolamine (GPE); inorganic phosphate (P(i)); phosphocholine (PC); phosphoethanolamine (PE); uridine diphosphate‐glucose (UDPG); nicotinamide adenine dinucleotide‐phosphate (NADH); and phosphatidylcholine (PtdC). Correction for hepatic lipid volume fraction (HLVF) was performed. STATISTICAL TESTS: Differences assessed by analysis of variance with Bonferroni correction for multiple comparison and with a Student's t‐test when appropriate. RESULTS: The concentrations for the young lean group corrected for HLVF were 2.56 ± 0.10 mM for γ‐ATP (mean ± standard deviation), α‐ATP: 2.42 ± 0.15 mM, GPC: 3.31 ± 0.27 mM, GPE: 3.38 ± 0.87 mM, P(i): 1.42 ± 0.20 mM, PC: 1.47 ± 0.24 mM, PE: 1.61 ± 0.20 mM, UDPG: 0.74 ± 0.17 mM, NADH: 1.21 ± 0.38 mM, and PtdC: 0.43 ± 0.10 mM. Differences found in ATP levels between lean and overweight volunteers vanished after HLVF correction. DATA CONCLUSION: Exploiting the excellent spectral resolution at 7T and using the phantom replacement method, we were able to quantify up to 10 (31)P‐containing hepatic metabolites. The combination of (31)P magnetic resonance spectroscopy imaging data acquisition and HLVF correction was not able to show a possible dependence of (31)P metabolite concentrations on BMI or age, in the small healthy population used in this study. Level of Evidence: 2 Technical Efficacy: Stage 1 J. Magn. Reson. Imaging 2019;49:597–607.
format Online
Article
Text
id pubmed-6586048
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-65860482019-06-27 Absolute Quantification of Phosphor‐Containing Metabolites in the Liver Using (31)P MRSI and Hepatic Lipid Volume Correction at 7T Suggests No Dependence on Body Mass Index or Age Pfleger, Lorenz Gajdošík, Martin Wolf, Peter Smajis, Sabina Fellinger, Paul Kuehne, Andre Krumpolec, Patrik Trattnig, Siegfried Winhofer, Yvonne Krebs, Michael Krššák, Martin Chmelík, Marek J Magn Reson Imaging Original Research BACKGROUND: Hepatic disorders are often associated with changes in the concentration of phosphorus‐31 ((31)P) metabolites. Absolute quantification offers a way to assess those metabolites directly but introduces obstacles, especially at higher field strengths (B(0) ≥ 7T). PURPOSE: To introduce a feasible method for in vivo absolute quantification of hepatic (31)P metabolites and assess its clinical value by probing differences related to volunteers' age and body mass index (BMI). STUDY TYPE: Prospective cohort. SUBJECTS/PHANTOMS: Four healthy volunteers included in the reproducibility study and 19 healthy subjects arranged into three subgroups according to BMI and age. Phantoms containing (31)P solution for correction and validation. FIELD STRENGTH/SEQUENCE: Phase‐encoded 3D pulse‐acquire chemical shift imaging for (31)P and single‐volume (1)H spectroscopy to assess the hepatocellular lipid content at 7T. ASSESSMENT: A phantom replacement method was used. Spectra located in the liver with sufficient signal‐to‐noise ratio and no contamination from muscle tissue, were used to calculate following metabolite concentrations: adenosine triphosphates (γ‐ and α‐ATP); glycerophosphocholine (GPC); glycerophosphoethanolamine (GPE); inorganic phosphate (P(i)); phosphocholine (PC); phosphoethanolamine (PE); uridine diphosphate‐glucose (UDPG); nicotinamide adenine dinucleotide‐phosphate (NADH); and phosphatidylcholine (PtdC). Correction for hepatic lipid volume fraction (HLVF) was performed. STATISTICAL TESTS: Differences assessed by analysis of variance with Bonferroni correction for multiple comparison and with a Student's t‐test when appropriate. RESULTS: The concentrations for the young lean group corrected for HLVF were 2.56 ± 0.10 mM for γ‐ATP (mean ± standard deviation), α‐ATP: 2.42 ± 0.15 mM, GPC: 3.31 ± 0.27 mM, GPE: 3.38 ± 0.87 mM, P(i): 1.42 ± 0.20 mM, PC: 1.47 ± 0.24 mM, PE: 1.61 ± 0.20 mM, UDPG: 0.74 ± 0.17 mM, NADH: 1.21 ± 0.38 mM, and PtdC: 0.43 ± 0.10 mM. Differences found in ATP levels between lean and overweight volunteers vanished after HLVF correction. DATA CONCLUSION: Exploiting the excellent spectral resolution at 7T and using the phantom replacement method, we were able to quantify up to 10 (31)P‐containing hepatic metabolites. The combination of (31)P magnetic resonance spectroscopy imaging data acquisition and HLVF correction was not able to show a possible dependence of (31)P metabolite concentrations on BMI or age, in the small healthy population used in this study. Level of Evidence: 2 Technical Efficacy: Stage 1 J. Magn. Reson. Imaging 2019;49:597–607. John Wiley and Sons Inc. 2018-10-06 2019-02 /pmc/articles/PMC6586048/ /pubmed/30291654 http://dx.doi.org/10.1002/jmri.26225 Text en © 2018 The Authors. Journal of Magnetic Resonance Imaging published by Wiley Periodicals, Inc. on behalf of International Society for Magnetic Resonance in Medicine. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Research
Pfleger, Lorenz
Gajdošík, Martin
Wolf, Peter
Smajis, Sabina
Fellinger, Paul
Kuehne, Andre
Krumpolec, Patrik
Trattnig, Siegfried
Winhofer, Yvonne
Krebs, Michael
Krššák, Martin
Chmelík, Marek
Absolute Quantification of Phosphor‐Containing Metabolites in the Liver Using (31)P MRSI and Hepatic Lipid Volume Correction at 7T Suggests No Dependence on Body Mass Index or Age
title Absolute Quantification of Phosphor‐Containing Metabolites in the Liver Using (31)P MRSI and Hepatic Lipid Volume Correction at 7T Suggests No Dependence on Body Mass Index or Age
title_full Absolute Quantification of Phosphor‐Containing Metabolites in the Liver Using (31)P MRSI and Hepatic Lipid Volume Correction at 7T Suggests No Dependence on Body Mass Index or Age
title_fullStr Absolute Quantification of Phosphor‐Containing Metabolites in the Liver Using (31)P MRSI and Hepatic Lipid Volume Correction at 7T Suggests No Dependence on Body Mass Index or Age
title_full_unstemmed Absolute Quantification of Phosphor‐Containing Metabolites in the Liver Using (31)P MRSI and Hepatic Lipid Volume Correction at 7T Suggests No Dependence on Body Mass Index or Age
title_short Absolute Quantification of Phosphor‐Containing Metabolites in the Liver Using (31)P MRSI and Hepatic Lipid Volume Correction at 7T Suggests No Dependence on Body Mass Index or Age
title_sort absolute quantification of phosphor‐containing metabolites in the liver using (31)p mrsi and hepatic lipid volume correction at 7t suggests no dependence on body mass index or age
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6586048/
https://www.ncbi.nlm.nih.gov/pubmed/30291654
http://dx.doi.org/10.1002/jmri.26225
work_keys_str_mv AT pflegerlorenz absolutequantificationofphosphorcontainingmetabolitesintheliverusing31pmrsiandhepaticlipidvolumecorrectionat7tsuggestsnodependenceonbodymassindexorage
AT gajdosikmartin absolutequantificationofphosphorcontainingmetabolitesintheliverusing31pmrsiandhepaticlipidvolumecorrectionat7tsuggestsnodependenceonbodymassindexorage
AT wolfpeter absolutequantificationofphosphorcontainingmetabolitesintheliverusing31pmrsiandhepaticlipidvolumecorrectionat7tsuggestsnodependenceonbodymassindexorage
AT smajissabina absolutequantificationofphosphorcontainingmetabolitesintheliverusing31pmrsiandhepaticlipidvolumecorrectionat7tsuggestsnodependenceonbodymassindexorage
AT fellingerpaul absolutequantificationofphosphorcontainingmetabolitesintheliverusing31pmrsiandhepaticlipidvolumecorrectionat7tsuggestsnodependenceonbodymassindexorage
AT kuehneandre absolutequantificationofphosphorcontainingmetabolitesintheliverusing31pmrsiandhepaticlipidvolumecorrectionat7tsuggestsnodependenceonbodymassindexorage
AT krumpolecpatrik absolutequantificationofphosphorcontainingmetabolitesintheliverusing31pmrsiandhepaticlipidvolumecorrectionat7tsuggestsnodependenceonbodymassindexorage
AT trattnigsiegfried absolutequantificationofphosphorcontainingmetabolitesintheliverusing31pmrsiandhepaticlipidvolumecorrectionat7tsuggestsnodependenceonbodymassindexorage
AT winhoferyvonne absolutequantificationofphosphorcontainingmetabolitesintheliverusing31pmrsiandhepaticlipidvolumecorrectionat7tsuggestsnodependenceonbodymassindexorage
AT krebsmichael absolutequantificationofphosphorcontainingmetabolitesintheliverusing31pmrsiandhepaticlipidvolumecorrectionat7tsuggestsnodependenceonbodymassindexorage
AT krssakmartin absolutequantificationofphosphorcontainingmetabolitesintheliverusing31pmrsiandhepaticlipidvolumecorrectionat7tsuggestsnodependenceonbodymassindexorage
AT chmelikmarek absolutequantificationofphosphorcontainingmetabolitesintheliverusing31pmrsiandhepaticlipidvolumecorrectionat7tsuggestsnodependenceonbodymassindexorage